ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential
https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Press Release
https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g
FREMONT, CA – March 19, 2025 (NEWMEDIAWIRE) – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, provides an update on its cash milestone payment…
read more